Clinical Verification on the Predictors for Febrile Neutropenia in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy

• Published in: Anticancer research 2023-01, Vol.43 (1), p.247-254
• Main Authors: Goto, Wataru, Kashiwagi, Shinichiro, Matsuoka, Kohei, Iimori, Nozomi, Kouhashi, Rika, Yabumoto, Akimichi, Takada, Koji, Asano, Yuka, Tauchi, Yukie, Ogisawa, Kana, Morisaki, Tamami, Shibutani, Masatsune, Tanaka, Hiroaki, Maeda, Kiyoshi
• Format: Article
• Language: English
• Subjects: Antineoplastic Combined Chemotherapy Protocols - adverse effects; Body mass; Body mass index; Body size; Breast cancer; Breast Neoplasms - drug therapy; Chemotherapy; Epidermal growth factor; Evaluation; Febrile Neutropenia - chemically induced; Febrile Neutropenia - diagnosis; Female; Granulocyte Colony-Stimulating Factor; Growth factors; Humans; Inflammation; Leukocytes; Lymphocytes; Medical prognosis; Neoadjuvant Therapy - adverse effects; Neutropenia; Prognosis; Receptors; Retrospective Studies; Survival
• ISSN: 0250-7005; 1791-7530
• DOI: 10.21873/anticanres.16156

Febrile neutropenia (FN) is a potentially life-threatening complication of chemotherapy. In this study, we evaluated the predictors for FN according to neoadjuvant chemotherapy (NAC) in all breast cancer subtypes. We examined 327 patients with breast cancer treated with NAC. The correlation between the development of FN and clinicopathological features, including systemic inflammatory markers, and prognosis was evaluated retrospectively. There were no significant differences between patients with and without FN in terms of disease-free survival or overall survival (p=0.562, p=0.149, log-rank, respectively). Low body mass index (BMI) (p